ERYTECH PHARMA SA (NASDAQ:ERYP) Q2 2020 Earnings Conference Call - Final Transcript
Sep 21, 2020 • 08:30 am ET
Ladies and gentlemen, thank you for standing by and welcome to the ERYTECH Business Update and Financial Highlights for the Second Quarter of 2020 Conference Call.
I would now like to hand the conference to your speaker today, Gil Beyen, Chief Executive Officer. Please go ahead, sir.
Thank you. Good afternoon, good morning. [Foreign Speech] Hoping you're all well and safe, and thanks for joining us for our earnings call for the second quarter of 2020 and the first half year.
We announced our business and financial update yesterday evening. You should be able to access the press release and our earnings presentation on the Investors page of our website under Webcasts and link to slide show or via the link that was provided in the press release. With me on this call in three different locations this time are Dr. Iman El-Hariry, our Chief Medical Officer; and Eric Soyer, our Chief Financial and Chief Operating Officer.
Turning to Page 2. And before starting, drawing your attention to disclaimer on Slide 2, and you'll see if you read it, COVID-19 is still there. We are overall succeeding well in minimizing its impact on our operations but the pandemic continues obviously to have an impact on our trials, as you will see in the in the update.
Turning to Slide 3, the agenda, so it's the usual quarterly routine. I will start with a short business update focusing on the key highlights for the second quarter and year-to-date. Eric will then present the financial results for the first half of the year and summarize the major news flow and expected milestones for the next 12 months, after which the three of us will be available to respond to your questions.
Slide 4 before starting the update for completeness, a quick reminder on our Company. It's a leader in red blood cells, especially focused on cancer and cancer metabolism. Our focus is on targeting cancer cells altered amino acid metabolism. With this, we are in three late stage, Phase 3 in pancreatic cancer, Phase 2 in triple-negative breast cancer and a Phase 2 in acute lymphoblastic leukemia. And as you know, we have our own production sites, one in Europe -- in Lyon, one for Europe in Lyon and one for U.S. in Princeton. We are listed on Euronext and on Nasdaq. So everything we do is really on the two continents.
The graph on the right side, just remind once, it's the survival curve of our Phase 2 study in second-line pancreatic cancer, which with a 40% reduction in risk of death rate is to our knowledge still the strongest result ever seen in a large clinical trial in second-line pancreatic cancer, and it's this Phase 2 that obviously enabled us to transition to our pivotal Phase 3 TRYbeCA-1, which will again be the main focus of this update.
And the highlights of the update are on Slide 5. It's not only TRYbeCA-1, I'll start with TRYbeCA-1, but there is